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Abstract 
Short Communication on t(8;12)(q13;p13) 
ETV6/NCOA2, with data on clinics, and the genes 
implicated. 
Clinics and pathology 
Disease 
T-cell acute lymphoblastic leukemia (T-ALL), B-
cell acute lymphoblastic leukemia (B-ALL), 
biphenotypic acute leukemia (BAL), and acute 
myeloid leukemia (AML). 
Phenotype/cell stem origin 
This entity most often appears as a childhood 
leukemia expressing both T-lymphoid and myeloid 
antigens. Eleven cases are available to date: one 
case of common B-ALL, 6 cases of T-ALL, 3 cases 
of BAL, and one M4-AML (Pui et al., 1987; 
Schneider et al., 2000; Yamamoto et al., 2002; 
Strehl et al., 2008; Zhou et al., 2012). 
Epidemiology 
There were 5 male and 6 female patients, aged 2, 2, 
2, 7, 8, 11, 14, 23, 75 years, and two additional 
cases came from a series of "childhood leukemia". 
Prognosis 
Although the sample is far too small for definitive 
conclusions, the prognosis does not seem bad (see 
Figure). 
Cytogenetics 
Cytogenetics morphological 
Breakpoints were difficult to assign accurately by  
conventional cytogenetics, with cases described 
with a t(8;12)(q10;p10), a t(8;12)(q11;p11), a 
t(8;12)(q12;p12), a t(8;12)(q12;p13), or a 
t(8;12)(q13;p13), but all exhibiting an 
ETV6/NCOA2 fusion transcript (Strehl et al., 
2008). The t(8;12) was the sole anomaly in five 
cases (four ALLs and one M1-AML/BAL), and was 
accompanied with a del(5q) in two ALL cases, a 
del(6q), a +9, and a del(11q) in an ALL each, a 
t(11;19)(q23;p13) in the M4-AML, and a +22 in a 
M1-AML/BAL. 
Genes involved and 
proteins 
Note 
Heterozygous NOTCH1 mutations were found in 
five of six samples where they were studied (Strehl 
et al., 2008; Zhou et al., 2012). 
NCOA2 
Location 
8q13.3 
Protein 
1464 amino acids. NCOA2 is composed of a basic 
helix-loop-helix (HLH), a PAS (Per/Arnt/Sim) 
region, four LXXLL motifs (L=leucine, X=any 
amino acid) that are critical for interaction with 
nuclear receptors, a LLXXLXXXL motif is 
involved in transcriptional coactivation and 
CREBBP/CBP binding, and a polyglutamine tract. 
Transcriptional coactivator for steroid receptors and 
nuclear receptors. Involved in skeletal muscle 
differentiation (Chen et al., 2000). Acts as a tumor 
suppressor in liver cancer (O'Donnell et al., 2012). 
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Overall survival in patients with t(8;12)(q13;p13) ETV6/NCOA9 (n=9). 
 
ETV6 
Location 
12p13.2 
Protein 
452 amino acids. ETV6 is composed of a HLH 
domain responsible for hetero- and 
homodimerization in N-term, and an ETS domain 
responsible for sequence specific DNA-binding in 
C-term (binds to the DNA sequence 5'-
CCGGAAGT-3'). Transcriptional regulator; tumor 
suppressor. Involved in bone marrow 
hematopoiesis. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
There was fusion of ETV6 exon 4 with NCOA2 
exon 15 in five of six cases, and fusion of ETV6 
exon 5 with NCOA2 exon 14 in one case (Strehl et 
al., 2008). 
Fusion protein 
Description 
Fuses the pointed or sterile alpha motif (SAM) 
oligomerization domain of ETV6 to the C-term 
poly Gln of NCOA2 (with or without the 
LLXXLXXXL motif of NCOA2). 
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